Complications and Occurrence of Exacerbations in Patients with Myasthenia Gravis Treated with Oral Corticosteroids
Oral steroids for myasthenia gravis carry high infection and bone risks, justifying aggressive adoption of newer steroid-sparing alternatives.
This large retrospective US claims study characterized OCS-related complications and disease exacerbations in myasthenia gravis patients stratified by OCS duration, finding that any OCS exposure conferred 60% higher infection risk and longer exposure increased osteoporosis risk by 70%. Paradoxically, OCS-exposed patients also experienced more MG exacerbations, reinforcing the clinical rationale for steroid-sparing complement inhibitors and FcRn antagonists approved in recent years.
What the study was
- Study design
- retrospective_longitudinal_cohort_claims
- Category
- rare_diseases
- Maturity
- Validated
- Journal
- Drugs Real World Outcomes
Why it surfaced
Large real-world claims study quantifying OCS burden in MG; data reinforces urgency for steroid-sparing novel agents; J&J-affiliated authors create potential bias; retrospective claims design limits causal inference.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.